BDBM621123 US20230303563, Compound 165

SMILES FC(F)c1ccc2ncc(-c3cccc(N[C@H]4CNC[C@@H]4F)n3)n2c1

InChI Key InChIKey=QSSMDRNGJZDMSQ-AAEUAGOBSA-N

Data  3 IC50  11 Kd

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 14 hits for monomerid = 621123   

TargetInterleukin-1 receptor-associated kinase 1(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621123(US20230303563, Compound 165)
Affinity DataIC50:  25nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621123(US20230303563, Compound 165)
Affinity DataIC50:  0.600nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621123(US20230303563, Compound 165)
Affinity DataIC50:  0.600nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621123(US20230303563, Compound 165)
Affinity DataKd:  0.170nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3 [D835H](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621123(US20230303563, Compound 165)
Affinity DataKd:  0.240nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621123(US20230303563, Compound 165)
Affinity DataKd:  0.0250nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3 [572-603](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621123(US20230303563, Compound 165)
Affinity DataKd:  4.90nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621123(US20230303563, Compound 165)
Affinity DataKd:  0.150nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621123(US20230303563, Compound 165)
Affinity DataKd:  0.00700nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [F691L](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621123(US20230303563, Compound 165)
Affinity DataKd:  0.190nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3 [K663Q](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621123(US20230303563, Compound 165)
Affinity DataKd:  1.60nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621123(US20230303563, Compound 165)
Affinity DataKd:  0.740nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3 [R834Q](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621123(US20230303563, Compound 165)
Affinity DataKd:  0.890nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3 (D835Y)(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621123(US20230303563, Compound 165)
Affinity DataKd:  0.110nMAssay Description:Table 33 and 34: Kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent